Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically ...

Glenmark Pharmaceuticals Ltd on Wednesday said its US arm has launched the generic version of Clindamycin Phosphate foam, an.

This new product is bioequivalent and therapeutically equivalent to the reference-listed drug, Evoclin Foam, 1%, manufactured ...

Glenmark Pharmaceuticals's US arm has launched a generic version of Clindamycin Phosphate foam, an antibiotic acne treatment.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...

Glenmark Pharmaceuticals Ltd's US division has introduced a generic version of Clindamycin Phosphate foam, an acne treatment. This product is equivalent to Mylan's Evoclin foam and joins a market with ...

Glenmark Pharmaceuticals has announced the launch of Clindamycin Phosphate Foam, which is a bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam of Mylan ...

According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million ...

Cosmo CEO Giovanni Di Napoli said the milestone underscores the company's commitment, alongside Glenmark, to provide patients ...

Glenmark Pharmaceuticals receives UK approval for Winlevi, a groundbreaking topical acne treatment with unique mechanism of ...

Dublin, Ireland and Mumbai, India and London, United Kingdom--( - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a ...

Glenmark Pharmaceuticals Ltd, in collaboration with Cosmo Pharmaceuticals N.V., has received approval from the UK Medicines ...